公开(公告)号：EP4458954A1

公开(公告)日：2024-11-06

申请号：EP22916047.8

申请日：2022-12-26

申请人： Sumitomo Pharma Co., Ltd.

发明人： TAHARA, Masahiro ,  FUJIKI, Ayaka ,  YOSHIDA, Kenji ,  KITAGAWA, Maiko

IPC分类号： C12N5/079 ,  A61K35/28 ,  A61P43/00 ,  C07K14/78 ,  C12N5/0775 ,  C12Q1/6851 ,  C12N5/10 ,  C12N15/12

摘要： The present invention aims to provide a culturing method and a method for producing a cell population containing a neural crest cell, the methods being able to stably mass produce the neural crest cell from a pluripotent stem cell with quality that allows the cell to be used in a therapy with a cell, and a method for producing a mesenchymal stem cell and the like using the neural crest cell. The method for selectively culturing a neural crest cell in a cell population containing a neural crest cell and/or a neural crest progenitor cell of the present invention comprises a culturing step of adherent culturing the cell population containing the neural crest cell and/or the neural crest progenitor cell, in the presence of one or more extracellular matrices selected from the group consisting of laminin with its α chain being an α1 chain and its β chain being a β1 chain, laminin with its α chain being an α2 chain and its β chain being a β1 chain, laminin with its α chain being an α2 chain and its β chain being a β2 chain, and laminin with its α chain being an α5 chain and its β chain being a β1 chain, and extracellular matrices containing integrin-binding sites of these laminins.

公开(公告)号：EP4448573A1

公开(公告)日：2024-10-23

申请号：EP22843648.1

申请日：2022-12-16

申请人： Universität Basel ,  Cimeio Therapeutics AG

发明人： URLINGER, Stefanie ,  LEPORE, Rosalba ,  JEKER, Lukas ,  WIEDERKEHR, Amélie ,  SINOPOLI, Alessandro ,  CAMUS, Anna ,  WELLINGER, Lisa ,  MATTER-MARONE, Romina

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K35/28 ,  C12N5/0789 ,  C12N15/113

公开(公告)号：EP3973970B1

公开(公告)日：2024-08-28

申请号：EP21195085.2

申请日：2008-03-21

IPC分类号： A61K35/28 ,  A61P11/00 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K2035/12220130101 ,  A61K2035/12420130101 ,  C12N5/0663 ,  A61P11/00

公开(公告)号：EP4415730A1

公开(公告)日：2024-08-21

申请号：EP22881736.7

申请日：2022-10-12

申请人： Mechanogenic K.K.

发明人： FUNAKI, Makoto

IPC分类号： A61K35/28 ,  A61K47/32 ,  A61K47/34 ,  A61P9/00 ,  C12N5/0775

CPC分类号： A61P9/00 ,  A61K35/28 ,  C12N5/0012 ,  C12N5/0667 ,  C12N2513/0020130101 ,  C12N2533/5020130101 ,  C12N2533/3020130101 ,  C12N2501/2520130101 ,  C12N2501/2420130101

公开(公告)号：EP4365299A3

公开(公告)日：2024-08-07

申请号：EP24163345.2

申请日：2019-05-16

申请人： Olives Biotherapeutics Inc.

发明人： PARK, Woo Jin ,  YOON, Aeri

IPC分类号： A61K38/18 ,  A61K39/395 ,  A61K31/7105 ,  A61K31/7088 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  A61K35/545 ,  A61K35/76 ,  A61P27/02 ,  C07K16/22 ,  C12N15/86

CPC分类号： A61P27/02 ,  A61K38/18 ,  C07K16/22 ,  A61K35/30 ,  A61K31/7088 ,  A61K35/545 ,  C12N15/86 ,  C12N2750/1414320130101 ,  C12N2750/1412320130101

摘要： The present invention relates to a pharmaceutical composition comprising CCN5 as an active ingredient, for preventing or treating retinal diseases, particularly wet macular degeneration. CCN5 according to the present invention prevents fibrotic changes, caused by TGF-β, EEF, or anti-VEGF drugs, in retinal pigment epithelial cells. In addition, CCNS recuperates the morphological or functional damage, caused by fibrotic changes, of retinal pigment epithelial cells to the level of normal cells. Therefore, the composition comprising CCNS as an active ingredient can be advantageously utilized for preventing or treating retinal diseases.

公开(公告)号：EP4402250A1

公开(公告)日：2024-07-24

申请号：EP22783679.8

申请日：2022-09-16

申请人： Life Technologies Corporation ,  NUNC A/S

发明人： JOHNSON, Debra ,  SPORRING, Sune

IPC分类号： C12N5/0775 ,  A61K35/28 ,  C12M3/00

CPC分类号： C12N5/0663 ,  C12N5/0667 ,  C12N5/0668 ,  C12N2500/9820130101 ,  C12N2500/9920130101 ,  C12N2533/3020130101 ,  A61K35/28

公开(公告)号：EP3903794B1

公开(公告)日：2024-07-24

申请号：EP19897870.2

申请日：2019-12-04

IPC分类号： A61K35/28 ,  C12N15/06 ,  A61P37/06

CPC分类号： A61P37/06 ,  A61K35/28 ,  A01K2207/3520130101 ,  C12N5/0663 ,  Y02A50/30

公开(公告)号：EP4394031A1

公开(公告)日：2024-07-03

申请号：EP23856254.0

申请日：2023-06-27

申请人： Shenzhen Beike Biotechnology Co., Ltd.

发明人： LIAO, Yan ,  FU, Zeqin ,  LI, Duanduan ,  YANG, Yulin ,  HUANG, Yinfu ,  CAI, Cheguo ,  HU, Junyuan

IPC分类号： C12N5/0775 ,  A61K35/28 ,  A61P37/02 ,  A61P29/00

摘要： The present invention discloses a mesenchymal stem cell treated by at least two of cytokines IL4, IL21, and IL27, an exosome and use thereof. The present invention relates to the technical field of biomedicine; the mesenchymal stem cell and exosome thereof are obtained after the mesenchymal stem cell is pretreated with a cytokine composition. The mesenchymal stem cell is pretreated in a way of: treating and stimulating the mesenchymal stem cell by stages with a complete medium containing the cytokine composition to obtain a capacitated mesenchymal stem cell; the exosome of the mesenchymal stem cell is pretreated in a way of: treating and stimulating the mesenchymal stem cell by stages with a complete medium containing the cytokine composition, and replacing with a basal medium for starvation treatment. The mesenchymal stem cell obtained after being pretreated with the cytokine composition and an exosome thereof provided in the present invention can exert a stronger immune modulating effect and thus, can be used for the treatment of immune diseases better.

公开(公告)号：EP4393499A1

公开(公告)日：2024-07-03

申请号：EP22383291.6

申请日：2022-12-27

申请人： Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana

发明人： Tejedor Gascón, Sandra ,  González-King Garibotti, Hernán ,  Buigues Caravaca, Marc ,  García, Nahuel Aquiles ,  Sepúlveda Sanchis, Pilar

IPC分类号： A61K35/28 ,  C07K14/54 ,  C07K14/705

CPC分类号： A61K35/28 ,  C07K14/7155 ,  C07K14/52

摘要： The present invention refers to an isolated Small Extracellular Vesicle (SEV) with a mutated form of functional Oncostatin M expressed on its surface. Further, pharmaceutical compositions comprising one or more SEVs, as active ingredient, are also contemplated. The invention also refers to an in vitro method for producing the SEVs of the invention, comprising the steps of a) immortalizing a human MSC line by telomerase overexpression, b) introducing in the immortalized MSCs a vector expression constituted by a genetic construct, comprising the modified OSM sequence, selected from SEQ ID NO 1 or SEQ ID NO 2, fused to CD81 sequence, and an inducible promoter, which responds to doxycycline, c) culturing the genetically modified MSCs obtained in b) in a medium culture under conditions permitting their expansion, d) adding doxocycline to the culture medium, and e) Collecting Small Extracellular vesicles (SEVs) from the culture supernatant.

公开(公告)号：EP4342978A3

公开(公告)日：2024-07-03

申请号：EP24153603.6

申请日：2017-08-31

申请人： Chimera Bioengineering Inc.

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K35/17 ,  A61K35/28 ,  A61K39/00 ,  A61K39/395 ,  C12N5/00

CPC分类号： C12N15/63 ,  C12N9/0008 ,  C12N9/96 ,  C12Y102/01012 ,  A61P35/00 ,  A61P35/02 ,  A61P37/04

摘要： The present invention relates to primary T-cells comprising a receptor, such as a chimeric antigen receptor, and a heterologous nucleic acid comprising a promoter operably linked to a polynucleotide encoding a transgene that is operably linked to a polynucleotide encoding a RNA degradation element (RDE), and optionally an RDE-binding protein, wherein the RDE is an AU rich element, wherein the heterologous nucleic acid is transcribed to make a transcript encoding the transgene operably linked to the RDE.